SPORANOX (itraconazole) Capsules should not be administered for the
treatment of onychomycosis in patients with evidence of ventricular
dysfunction such as congestive heart failure (CHF) or a history of CHF. If
signs or symptoms of congestive heart failure occur during administration of
SPORANOX Capsules, discontinue administration. When itraconazole was
administered intravenously to dogs and healthy human volunteers, negative inotropic
effects were seen. (See CLINICAL PHARMACOLOGY: Special Populations,
CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug Interactions and
ADVERSE REACTIONS: Post-marketing Experience for more information.)
Drug Interactions: Coadministration of cisapride, pimozide, quinidine, or
dofetilide with SPORANOX� (itraconazole) Capsules, Injection or Oral
Solution is contraindicated. SPORANOX�, a potent cytochrome P450 3A4
isoenzyme system (CYP3A4) inhibitor, may increase plasma concentrations of
drugs metabolized by this pathway. Serious cardiovascular events, including QT
prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and/or
sudden death have occurred in patients using cisapride, pimozide, or quinidine,
concomitantly with SPORANOX� and/or other CYP3A4 inhibitors. See
CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactions for
more information.
DESCRIPTION
SPORANOX� is the brand name for itraconazole, a synthetic triazole antifungal agent.
Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs),
each possessing three chiral centers. It may be represented by the following structural
formula and nomenclature:
(�)-1-[(R*)-sec-butyl]-4-[p-[4-[p-[[(2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-
ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-A2-1,2,4-triazolin-5-one
mixture with (�)-1-[(R*)-sec-butyl]-4-[p-[4-[p-[[(2S*,4R*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-
triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-A 2-1,2,4-triazolin-
5-one
or
(�)-1-[(RS)-sec-butyl]-4-[p-[4-[p-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-
ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-A2 2-1,2,4-triazolin-5-one
Itraconazole has a molecular formula of C35H38Cl2N8O4 and a molecular weight of 705.64. It
is a white to slightly yellowish powder. It is insoluble in water, very slightly soluble in
alcohols, and freely soluble in dichloromethane. It has a pKa of 3.70 (based on
extrapolation of values obtained from methanolic solutions) and a log (n-octanol/water)
partition coefficient of 5.66 at pH 8.1.
SPORANOX� Capsules contain 100 mg of itraconazole coated on sugar spheres. Inactive
ingredients are gelatin, hydroxypropyl methylcellulose, polyethylene glycol (PEG) 20,000,
starch, sucrose, titanium dioxide, FD&C Blue No. 1, FD&C Blue No. 2, D&C Red No. 22
and D&C Red No. 28.
CLINICAL PHARMACOLOGY
CHF Labeling � 050101 (clean) 3
05/08/01
Pharmacokinetics and Metabolism: NOTE: The plasma concentrations reported below
were measured by high-performance liquid chromatography (HPLC) specific for
itraconazole. When itraconazole in plasma is measured by a bioassay, values reported are
approximately 3.3 times higher than those obtained by HPLC due to the presence of the
bioactive metabolite, hydroxyitraconazole. (See MICROBIOLOGY.)
The pharmacokinetics of itraconazole after intravenous administration and its absolute oral
bioavailability from an oral solution were studied in a randomized crossover study in 6
healthy male volunteers. The observed absolute oral bioavailability of itraconazole was
55%.
The oral bioavailability of itraconazole is maximal when SPORANOX� (itraconazole)
Capsules are taken with a full meal. The pharmacokinetics of itraconazole were studied in
6 healthy male volunteers who received, in a crossover design, single 100-mg doses of
itraconazole as a polyethylene glycol capsule, with or without a full meal. The same 6
volunteers also received 50 mg or 200 mg with a full meal in a crossover design. In this
study, only itraconazole plasma concentrations were measured. The respective
pharmacokinetic parameters for itraconazole are presented in the table below:
*mean + standard deviation
Doubling the SPORANOX� dose results in approximately a three-fold increase in the
itraconazole plasma concentrations.
Values given in the table below represent data from a crossover pharmacokinetics study in
which 27 healthy male volunteers each took a single 200-mg dose of SPORANOX�
Capsules with or without a full meal:
*mean � standard deviation
Absorption of itraconazole under fasted conditions in individuals with relative or absolute
achlorhydria, such as patients with AIDS or volunteers taking gastric acid secretion
suppressors (e.g., H2 receptor antagonists), was increased when SPORANOX� Capsules
were administered with a cola beverage. Eighteen men with AIDS received single 200-mg
doses of SPORANOX� Capsules under fasted conditions with 8 ounces of water or 8
ounces of a cola beverage in a crossover design. The absorption of itraconazole was
increased when SPORANOX� Capsules were coadministered with a cola beverage, with
AUC0-24 and Cmax increasing 75% � 121% and 95% � 128%, respectively.
Thirty healthy men received single 200-mg doses of SPORANOX� Capsules under fasted
conditions either 1) with water; 2) with water, after ranitidine 150 mg b.i.d. for 3 days; or 3)
with cola, after ranitidine 150 mg b.i.d. for 3 days. When SPORANOX� Capsules were
administered after ranitidine pretreatment, itraconazole was absorbed to a lesser extent
than when SPORANOX� Capsules were administered alone, with decreases in AUC0-24
and Cmax of 39% � 37% and 42% � 39%, respectively. When SPORANOX� Capsules
were administered with cola after ranitidine pretreatment, itraconazole absorption was
comparable to that observed when SPORANOX� Capsules were administered alone. (See
PRECAUTIONS: Drug Interactions.)
Steady-state concentrations were reached within 15 days following oral doses of 50 mg to
400 mg daily. Values given in the table below are data at steady-state from a
pharmacokinetics study in which 27 healthy male volunteers took 200-mg SPORANOX�
Capsules b.i.d.(with a full meal) for 15 days:
*mean � standard deviation
The plasma protein binding of itraconazole is 99.8% and that of hydroxyitraconazole is
99.5%. Following intravenous administration, the volume of distribution of itraconazole
averaged 796 � 185 liters.
Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system
(CYP3A4), resulting in the formation of several metabolites, including hydroxyitraconazole,
the major metabolite. Results of a pharmacokinetics study suggest that itraconazole may
undergo saturable metabolism with multiple dosing. Fecal excretion of the parent drug
varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of
the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single
excreted metabolite represents more than 5% of a dose. Itraconazole total plasma
clearance averaged 381 � 95 mL/minute following intravenous administration. (See
CONTRAINDICATIONS and PRECAUTIONS: Drug Interactions for more information.)
Special Populations:
Renal Insufficiency: A pharmacokinetic study using a single 200-mg dose of
itraconazole (four 50-mg capsules) was conducted in three groups of patients with renal
impairment (uremia: n=7; hemodialysis: n=7; and continuous ambulatory peritoneal dialysis:
n=5). In uremic subjects with a mean creatinine clearance of 13 mL/min. x 1.73 m2, the
bioavailability was slightly reduced compared with normal population parameters. This
study did not demonstrate any significant effect of hemodialysis or continuous ambulatory
peritoneal dialysis on the pharmacokinetics of itraconazole (Tmax, Cmax, and AUC0-8).
Plasma concentration-versus-time profiles showed wide intersubject variation in all three
groups.
Hepatic Insufficiency: A pharmacokinetic study using a single 100-mg dose of
itraconazole (one 100-mg capsule) was conducted in 6 healthy and 12 cirrhotic subjects. No
statistically significant differences in AUC were seen between these two groups. A
statistically significant reduction in mean Cmax (47%) and a twofold increase in the
elimination half-life (37 � 17 hours) of itraconazole were noted in cirrhotic subjects
compared with healthy subjects. Patients with impaired hepatic function should be carefully
monitored when taking itraconazole. The prolonged elimination half-life of itraconazole
observed in cirrhotic patients should be considered when deciding to initiate therapy with
other medications metabolized by CYP3A4. (See BOX WARNING,
CONTRAINDICATIONS, and PRECAUTIONS: Drug Interactions.)
Decreased Cardiac Contractility: When itraconazole was administered intravenously to
anesthetized dogs, a dose-related negative inotropic effect was documented. In a healthy
volunteer study of SPORANOX Injection (intravenous infusion), transient, asymptomatic
decreases in left ventricular ejection fraction were observed using gated SPECT imaging;
these resolved before the next infusion, 12 hours later. If signs or symptoms of congestive
heart failure appear during administration of SPORANOX Capsules, SPORANOX should
be discontinued. (See CONTRAINDICATIONS, WARNINGS, PRECAUTIONS: Drug
Interactions and ADVERSE REACTIONS: Post-marketing Experience for more
information.)
MICROBIOLOGY
Mechanism of Action: In vitro studies have demonstrated that itraconazole inhibits the
cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal
cell membranes.
Activity In Vitro and In Vivo: Itraconazole exhibits in vitro activity against Blastomyces
dermatitidis, Histoplasma capsulatum, Histoplasma duboisii, Aspergillus flavus,
Aspergillus fumigatus, Candida albicans, and Cryptococcus neoformans. Itraconazole
also exhibits varying in vitro activity against Sporothrix schenckii, Trichophyton species,
Candida krusei, and other Candida species. The bioactive metabolite,
hydroxyitraconazole, has not been evaluated against Histoplasma capsulatum and
Blastomyces dermatitidis. Correlation between minimum inhibitory concentration (MIC)
results in vitro and clinical outcome has yet to be established for azole antifungal agents.
Itraconazole administered orally was active in a variety of animal models of fungal infection
using standard laboratory strains of fungi. Fungistatic activity has been demonstrated
against disseminated fungal infections caused by Blastomyces dermatitidis, Histoplasma
duboisii, Aspergillus fumigatus, Coccidioides immitis, Cryptococcus neoformans,
Paracoccidioides brasiliensis, Sporothrix schenckii, Trichophyton rubrum, and
Trichophyton mentagrophytes.
Itraconazole administered at 2.5 mg/kg and 5 mg/kg via the oral and parenteral routes
increased survival rates and sterilized organ systems in normal and immunosuppressed
guinea pigs with disseminated Aspergillus fumigatus infections. Oral itraconazole
administered daily at 40 mg/kg and 80 mg/kg increased survival rates in normal rabbits with
disseminated disease and in immunosuppressed rats with pulmonary Aspergillus
fumigatus infection, respectively. Itraconazole has demonstrated antifungal activity in a
variety of animal models infected with Candida albicans and other Candida species.
Resistance: Isolates from several fungal species with decreased susceptibility to
itraconazole have been isolated in vitro and from patients receiving prolonged therapy.
Several in vitro studies have reported that some fungal clinical isolates, including Candida
species, with reduced susceptibility to one azole antifungal agent may also be less
susceptible to other azole derivatives. The finding of cross-resistance is dependent on a
number of factors, including the species evaluated, its clinical history, the particular azole
compounds compared, and the type of susceptibility test that is performed. The relevance
of these in vitro susceptibility data to clinical outcome remains to be elucidated.
Studies (both in vitro and in vivo) suggest that the activity of amphotericin B may be
suppressed by prior azole antifungal therapy. As with other azoles, itraconazole inhibits the
14C-demethylation step in the synthesis of ergosterol, a cell wall component of fungi.
Ergosterol is the active site for amphotericin B. In one study the antifungal activity of
amphotericin B against Aspergillus fumigatus infections in mice was inhibited by
ketoconazole therapy. The clinical significance of test results obtained in this study is
unknown.
INDICATIONS AND USAGE
SPORANOX (itraconazole) Capsules are indicated for the treatment of the following fungal
infections in immunocompromised and non-immunocompromised patients:
2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, nonmeningeal
histoplasmosis, and
3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who
are refractory to amphotericin B therapy.
Specimens for fungal cultures and other relevant laboratory studies (wet mount,
histopathology, serology) should be obtained before therapy to isolate and identify
causative organisms. Therapy may be instituted before the results of the cultures and other
laboratory studies are known; however, once these results become available, antiinfective
therapy should be adjusted accordingly.
SPORANOX Capsules are also indicated for the treatment of the following fungal
infections in non-immunocompromised patients:
1. Onychomycosis of the toenail, with or without fingernail involvement, due to
dermatophytes (tinea unguium), and
2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium).
Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH
preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of
onychomycosis.
(See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS,
WARNINGS, and ADVERSE REACTIONS: Post-marketing Experience for more
information).
DESCRIPTION OF CLINICAL STUDIES
Blastomycosis: Analyses were conducted on data from two open-label, non-concurrently
controlled studies (N=73 combined) in patients with normal or abnormal immune status.
The median dose was 200 mg/day. A response for most signs and symptoms was
observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6
months. Results of these two studies demonstrated substantial evidence of the
effectiveness of itraconazole for the treatment of blastomycosis compared with the natural
history of untreated cases.
Histoplasmosis: Analyses were conducted on data from two open-label, non-concurrently
controlled studies (N=34 combined) in patients with normal or abnormal immune status (not
including HIV-infected patients). The median dose was 200 mg/day. A response for most
signs and symptoms was observed within the first 2 weeks, and all signs and symptoms
cleared between 3 and 12 months. Results of these two studies demonstrated substantial
evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared
with the natural history of untreated cases.
Histoplasmosis in HIV-infected patients: Data from a small number of HIV-infected
patients suggested that the response rate of histoplasmosis in HIV-infected patients is
similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in
HIV-infected patients is more severe and usually requires maintenance therapy to prevent
relapse.
Aspergillosis: Analyses were conducted on data from an open-label, �single-patient-use�
protocol designed to make itraconazole available in the U.S. for patients who either failed
or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by
two smaller open-label studies (N=31 combined) in the same patient population. Most adult
patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3
months. Results of these studies demonstrated substantial evidence of effectiveness of
itraconazole as a second-line therapy for the treatment of aspergillosis compared with the
natural history of the disease in patients who either failed or were intolerant of amphotericin
B therapy.
Onychomycosis of the fingernail: Analyses were conducted on data from a
double-blind, placebo-controlled study (N=73 total; 37 given SPORANOX Capsules) in
which patients with onychomycosis of the fingernails received a 1-week course (pulse) of
200 mg of SPORANOX Capsules b.i.d., followed by a 3-week period without
SPORANOX, which was followed by a second 1-week pulse of 200 mg of SPORANOX
Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent
(56%) of patients were considered an overall success and 47% of patients demonstrated
mycologic cure plus clinical cure. The mean time to overall success was approximately 5
months. None of the patients who achieved overall success relapsed.
CONTRAINDICATIONS
Congestive Heart Failure: SPORANOX (itraconazole) Capsules should not be
administered for the treatment of onychomycosis in patients with evidence of ventricular
dysfunction such as congestive heart failure (CHF) or a history of CHF. (See CLINICAL
PHARMACOLOGY: Special Populations, WARNINGS, PRECAUTIONS: Drug Interactions-
Calcium Channel Blockers, and ADVERSE REACTIONS: Post-marketing Experience.)
DRUG INTERACTIONS
Concomitant administration of SPORANOX (itraconazole) Capsules,
Injection, or Oral Solution and certain drugs metabolized by the cytochrome P450 3A4
isoenzyme system (CYP3A4) may result in increased plasma concentrations of those
drugs, leading to potentially serious and/or life-threatening adverse events. Cisapride, oral
midazolam, pimozide, quinidine, dofetilide, and triazolam are contraindicated with
SPORANOX. HMG CoA-reductase inhibitors metabolized by CYP3A4, such as lovastatin
and simvastatin, are also contraindicated with SPORANOX. (See BOX WARNING, and
PRECAUTIONS: Drug Interactions.)
SPORANOX should not be administered for the treatment of onychomycosis to pregnant
patients or to women contemplating pregnancy.
SPORANOX is contraindicated for patients who have shown hypersensitivity to
itraconazole or its excipients. There is no information regarding cross-hypersensitivity
between itraconazole and other azole antifungal agents. Caution should be used when
prescribing SPORANOX to patients with hypersensitivity to other azoles.
WARNINGS AND PRECAUTIONS
WARNINGS
SPORANOX (itraconazole) Capsules and SPORANOX Oral Solution should not be used
interchangeably. This is because drug exposure is greater with the Oral Solution than with
the Capsules when the same dose of drug is given. In addition, the topical effects of
mucosal exposure may be different between the two formulations. Only the Oral Solution
has been demonstrated effective for oral and/or esophageal candidiasis.
Hepatic Effects: SPORANOX has been associated with rare cases of serious
hepatotoxicity, including liver failure and death. Some of these cases had neither preexisting
liver disease nor a serious underlying medical condition. If clinical signs or
symptoms develop that are consistent with liver disease, the risks and benefits of continued
SPORANOX use should be reassessed. (See PRECAUTIONS: Information for Patients
and ADVERSE REACTIONS.)
Cardiac Dysrhythmias: Life-threatening cardiac dysrhythmias and/or sudden death have
occurred in patients using cisapride, pimozide, or quinidine concomitantly with
SPORANOX and/or other CYP3A4 inhibitors. Concomitant administration of these drugs
with SPORANOX is contraindicated. (See BOX WARNING, CONTRAINDICATIONS, and PRECAUTIONS: Drug Interactions.)
Cardiac Disease: SPORANOX Capsules should not be administered for the
treatment of onychomycosis in patients with evidence of ventricular dysfunction
such as congestive heart failure (CHF) or a history of CHF. SPORANOX Capsules
should not be used for other indications in patients with evidence of ventricular dysfunction
unless the benefit clearly outweighs the risk.
For patients with risk factors for congestive heart failure, physicians should carefully review
the risks and benefits of SPORANOX therapy. These risk factors include cardiac disease
such as ischemic and valvular disease; significant pulmonary disease such as chronic
obstructive pulmonary disease; and renal failure and other edematous disorders. Such
patients should be informed of the signs and symptoms of CHF, should be treated with
caution, and should be monitored for signs and symptoms of CHF during treatment. If signs
or symptoms of CHF appear during administration of SPORANOX Capsules, discontinue
administration.
When itraconazole was administered intravenously to anesthetized dogs, a dose-related
negative inotropic effect was documented. In a healthy volunteer study of SPORANOX
Injection (intravenous infusion), transient, asymptomatic decreases in left ventricular ejection
fraction were observed using gated SPECT imaging; these resolved before the next
infusion, 12 hours later.
Cases of CHF, peripheral edema, and pulmonary edema have been reported in the postmarketing
period among patients being treated for onychomycosis and/or systemic fungal
infections. (See CLINICAL PHARMACOLOGY: Special Populations,
CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions, and ADVERSE REACTIONS:
Post-marketing Experience for more information.)
PRECAUTIONS
General: Hepatic enzyme test values should be monitored in patients with pre-existing
hepatic function abnormalities or those who have experienced liver toxicity with other
medications. Hepatic enzyme test values should be monitored periodically in all patients
receiving continuous treatment for more than 1 month, or at any time a patient develops
signs or symptoms suggestive of liver dysfunction.
SPORANOX (itraconazole) Capsules should be administered after a full meal. (See
CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism.)
Under fasted conditions, itraconazole absorption was decreased in the presence of
decreased gastric acidity. The absorption of itraconazole may be decreased with the
concomitant administration of antacids or gastric acid secretion suppressors. Studies
conducted under fasted conditions demonstrated that administration with 8 ounces of a cola
beverage resulted in increased absorption of itraconazole in AIDS patients with relative or
absolute achlorhydria. This increase relative to the effects of a full meal is unknown. (See
CLINICAL PHARMACOLOGY: Pharmacokinetics and Metabolism.)
Information for Patients:
The topical effects of mucosal exposure may be different between the SPORANOX�
Capsules and Oral Solution. Only the Oral Solution has been demonstrated effective for
oral and/or esophageal candidiasis. SPORANOX� Capsules should not be used
interchangeably with SPORANOX� Oral Solution.
Instruct patients to take SPORANOX Capsules with a full meal.
Instruct patients about the signs and symptoms of congestive heart failure, and if these
signs or symptoms occur during SPORANOX administration, they should discontinue
SPORANOX and contact their healthcare provider immediately.
Instruct patients to report any signs and symptoms that may suggest liver dysfunction so
that the appropriate laboratory testing can be done. Such signs and symptoms may
include unusual fatigue, anorexia, nausea and/or vomiting, jaundice, dark urine, or pale
stools.
Instruct patients to contact their physician before taking any concomitant medications
with itraconazole to ensure there are no potential drug interactions.
Drug Interactions: Itraconazole and its major metabolite, hydroxyitraconazole, are
inhibitors of CYP3A4. Therefore, the following drug interactions may occur
(See Table 1 below and the following drug class subheadings that follow):
1. SPORANOX may decrease the elimination of drugs metabolized by CYP3A4, resulting
in increased plasma concentrations of these drugs when they are administered with
SPORANOX. These elevated plasma concentrations may increase or prolong both
therapeutic and adverse effects of these drugs. Whenever possible, plasma
concentrations of these drugs should be monitored, and dosage adjustments made after
concomitant SPORANOX therapy is initiated. When appropriate, clinical monitoring
for signs or symptoms of increased or prolonged pharmacologic effects is advised.
Upon discontinuation, depending on the dose and duration of treatment, itraconazole
plasma concentrations decline gradually (especially in patients with hepatic cirrhosis or
in those receiving CYP3A4 inhibitors). This is particularly important when initiating
therapy with drugs whose metabolism is affected by itraconazole.
2. Inducers of CYP3A4 may decrease the plasma concentrations of itraconazole.
SPORANOX may not be effective in patients concomitantly taking SPORANOX and
one of these drugs. Therefore, administration of these drugs with SPORANOX is not
recommended.
3. Other inhibitors of CYP3A4 may increase the plasma concentrations of itraconazole.
Patients who must take SPORANOX concomitantly with one of these drugs should be
monitored closely for signs or symptoms of increased or prolonged pharmacologic
effects of SPORANOX.
Table 1. Selected Drugs that are predicted to alter the plasma concentration
of itraconazole or have their plasma concentration altered by SPORANOX 1 1This list is not all-inclusive.
2Contraindicated with SPORANOX based on clinical and/or pharmacokinetics studies.
(See WARNINGS and below.)
3For information on parenterally administered midazolam, see the Benzodiazepine
paragraph below.
Antiarrhythmics: The class IA antiarrhythmic quinidine and class III antiarrhythmic
dofetilide are known to prolong the QT interval. Coadministration of quinidine or dofetilide
with SPORANOX may increase plasma concentrations of quinidine or dofetilide which
could result in serious cardiovascular events. Therefore, concomitant administration of
SPORANOX and quinidine or dofetilide is contraindicated. (See BOX WARNING,
Concomitant administration of digoxin and SPORANOX has led to increased plasma
concentrations of digoxin.
Anticonvulsants: Reduced plasma concentrations of itraconazole were reported when
SPORANOX was administered concomitantly with phenytoin. Carbamazepine,
phenobarbital, and phenytoin are all inducers of CYP3A4. Although interactions with
carbamazepine and phenobarbital have not been studied, concomitant administration of
SPORANOX and these drugs would be expected to result in decreased plasma
concentrations of itraconazole. In addition, in vivo studies have demonstrated an increase
in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole.
Although there are no data regarding the effect of itraconazole on carbamazepine
metabolism, because of the similarities between ketoconazole and itraconazole,
concomitant administration of SPORANOX and carbamazepine may inhibit the
metabolism of carbamazepine.
Antimycobacterials: Drug interaction studies have demonstrated that plasma
concentrations of azole antifungal agents and their metabolites, including itraconazole and
hydroxyitraconazole, were significantly decreased when these agents were given
concomitantly with rifabutin or rifampin. In vivo data suggest that rifabutin is metabolized in
part by CYP3A4. SPORANOX� may inhibit the metabolism of rifabutin. Although no formal
study data are available for isoniazid, similar effects should be anticipated. Therefore, the
efficacy of SPORANOX could be substantially reduced if given concomitantly with one of
these agents. Coadministration is not recommended.
Antineoplastics: SPORANOX may inhibit the metabolism of busulfan, docetaxel, and
vinca alkaloids.
Antipsychotics: Pimozide is known to prolong the QT interval and is partially metabolized
by CYP3A4. Coadministration of pimozide with SPORANOX� could result in serious
cardiovascular events. Therefore, concomitant administration of SPORANOX and
CHF Labeling � 050101 (clean) 17
pimozide is contraindicated. (See BOX WARNING, CONTRAINDICATIONS, and
WARNINGS.)
Benzodiazepines: Concomitant administration of SPORANOX and alprazolam,
diazepam, oral midazolam, or triazolam could lead to increased plasma concentrations of
these benzodiazepines. Increased plasma concentrations could potentiate and prolong
hypnotic and sedative effects. Concomitant administration of SPORANOX and oral
midazolam or triazolam is contraindicated. (See CONTRAINDICATIONS and WARNINGS.)
If midazolam is administered parenterally, special precaution and patient monitoring is
required since the sedative effect may be prolonged.
Calcium Channel Blockers: Edema has been reported in patients concomitantly
receiving SPORANOX and dihydropyridine calcium channel blockers. Appropriate
dosage adjustment may be necessary.
Calcium channel blockers can have a negative inotropic effect which may be additive to
those of itraconazole; itraconazole can inhibit the metabolism of calcium channel blockers
such as dihydropyridines (e.g., nifedipine and felodipine) and verapamil. Therefore, caution
should be used when co-administering itraconazole and calcium channel blockers. (See
CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS,
and ADVERSE REACTIONS: Post-marketing Experience for more information).
Gastric Acid Suppressors/Neutralizers: Reduced plasma concentrations of
itraconazole were reported when SPORANOX Capsules were administered concomitantly
with H2-receptor antagonists. Studies have shown that absorption of itraconazole is
impaired when gastric acid production is decreased. Therefore, SPORANOX should be
administered with a cola beverage if the patient has achlorhydria or is taking H2-receptor
antagonists or other gastric acid suppressors. Antacids should be administered at least 1
hour before or 2 hours after administration of SPORANOX Capsules. In a clinical study,
when SPORANOX Capsules were administered with omeprazole (a proton pump
inhibitor), the bioavailability of itraconazole was significantly reduced.
Gastrointestinal Motility Agents: Coadministration of SPORANOX� with cisapride can
elevate plasma cisapride concentrations which could result in serious cardiovascular
events. Therefore, concomitant administration of SPORANOX with cisapride is
contraindicated. (See BOX WARNING, CONTRAINDICATIONS, and WARNINGS.)
HMG CoA-Reductase Inhibitors: Human pharmacokinetic data suggest that
SPORANOX inhibits the metabolism of atorvastatin, cerivastatin, lovastatin, and
simvastatin, which may increase the risk of skeletal muscle toxicity, including
rhabdomyolysis. Concomitant administration of SPORANOX with HMG CoA-reductase
inhibitors, such as lovastatin and simvastatin, is contraindicated. (See
CONTRAINDICATIONS and WARNINGS.)
Immunosuppressants: Concomitant administration of SPORANOX and cyclosporine or
tacrolimus has led to increased plasma concentrations of these immunosuppressants.
Concomitant administration of SPORANOX� and sirolimus could increase plasma
concentrations of sirolimus.
Macrolide Antibiotics: Erythromycin and clarithromycin are known inhibitors of CYP3A4
(See Table 1) and may increase plasma concentrations of itraconazole. In a small
pharmacokinetic study involving HIV infected patients, clarithromycin was shown to increase
plasma concentrations of itraconazole. Similarly, following administration of 1 gram of
erythromycin ethyl succinate and 200 mg itraconazole as single doses, the mean Cmax and
AUC 0-� of itraconazole increased by 44% (90% CI: 119-175%) and 36% (90% CI: 108-
171%), respectively.
Non-nucleoside Reverse Transcriptase Inhibitors: Nevirapine is an inducer of
CYP3A4. In vivo studies have shown that nevirapine induces the metabolism of
ketoconazole, significantly reducing the bioavailability of ketoconazole. Studies involving
nevirapine and itraconazole have not been conducted. However, because of the similarities
between ketoconazole and itraconazole, concomitant administration of SPORANOX and
nevirapine is not recommended.
In a clinical study, when 8 HIV-infected subjects were treated concomitantly with
SPORANOX Capsules 100 mg twice daily and the nucleoside reverse transcriptase
inhibitor zidovudine 8 � 0.4 mg/kg/day, the pharmacokinetics of zidovudine were not
affected. Other nucleoside reverse transcriptase inhibitors have not been studied.
Oral Hypoglycemic Agents: Severe hypoglycemia has been reported in patients
concomitantly receiving azole antifungal agents and oral hypoglycemic agents. Blood
glucose concentrations should be carefully monitored when SPORANOX� and oral
hypoglycemic agents are coadministered.
Polyenes: Prior treatment with itraconazole, like other azoles, may reduce or inhibit the
activity of polyenes such as amphotericin B. However, the clinical significance of this drug
effect has not been clearly defined.
Protease Inhibitors: Concomitant administration of SPORANOX and protease
inhibitors metabolized by CYP3A4, such as indinavir, ritonavir, and saquinavir, may
increase plasma concentrations of these protease inhibitors. In addition, concomitant
administration of SPORANOX and indinavir and ritonavir (but not saquinavir) may
increase plasma concentrations of itraconazole. Caution is advised when SPORANOX
and protease inhibitors must be given concomitantly.
Other:
In vitro data suggest that alfentanil is metabolized by CYP3A4. Administration with
SPORANOX may increase plasma concentrations of alfentanil.
Human pharmacokinetic data suggest that concomitant administration of SPORANOX
and buspirone results in significant increases in plasma concentrations of buspirone.
SPORANOX may inhibit the metabolism of methylprednisolone.
In vitro data suggest that trimetrexate is extensively metabolized by CYP3A4. In vitro
animal models have demonstrated that ketoconazole potently inhibits the metabolism of
trimetrexate. Although there are no data regarding the effect of itraconazole on
trimetrexate metabolism, because of the similarities between ketoconazole and
itraconazole, concomitant administration of SPORANOX and trimetrexate may inhibit
the metabolism of trimetrexate.
SPORANOX enhances the anticoagulant effect of coumarin-like drugs, such as
warfarin.
Carcinogenesis, Mutagenesis, and Impairment of Fertility: Itraconazole showed no
evidence of carcinogenicity potential in mice treated orally for 23 months at dosage levels
up to 80 mg/kg/day (approximately 10x the maximum recommended human dose [MRHD]).
Male rats treated with 25 mg/kg/day (3.1x MRHD) had a slightly increased incidence of soft
tissue sarcoma. These sarcomas may have been a consequence of hypercholesterolemia,
which is a response of rats, but not dogs or humans, to chronic itraconazole administration.
Female rats treated with 50 mg/kg/day (6.25x MRHD) had an increased incidence of
squamous cell carcinoma of the lung (2/50) as compared to the untreated group. Although
the occurrence of squamous cell carcinoma in the lung is extremely uncommon in untreated
rats, the increase in this study was not statistically significant.
Itraconazole produced no mutagenic effects when assayed in DNA repair test (unscheduled
DNA synthesis) in primary rat hepatocytes, in Ames tests with Salmonella typhimurium (6
strains) and Escherichia coli, in the mouse lymphoma gene mutation tests, in a sex-linked
recessive lethal mutation (Drosophila melanogaster) test, in chromosome aberration tests
in human lymphocytes, in a cell transformation test with C3H/10T� C18 mouse embryo
fibroblasts cells, in a dominant lethal mutation test in male and female mice, and in
micronucleus tests in mice and rats.
Itraconazole did not affect the fertility of male or female rats treated orally with dosage levels
of up to 40 mg/kg/day (5x MRHD), even though parental toxicity was present at this dosage
level. More severe signs of parental toxicity, including death, were present in the next higher
dosage level, 160 mg/kg/day (20x MRHD).
Pregnancy: Teratogenic effects. Pregnancy Category C: Itraconazole was found to
cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats
at dosage levels of approximately 40-160 mg/kg/day (5-20x MRHD), and in mice at dosage
levels of approximately 80 mg/kg/day (10x MRHD). In rats, the teratogenicity consisted of
major skeletal defects; in mice, it consisted of encephaloceles and/or macroglossia.
There are no studies in pregnant women. SPORANOX should be used for the treatment of
systemic fungal infections in pregnancy only if the benefit outweighs the potential risk.
SPORANOX should not be administered for the treatment of onychomycosis to pregnant
patients or to women contemplating pregnancy. SPORANOX should not be administered
to women of childbearing potential for the treatment of onychomycosis unless they are using
effective measures to prevent pregnancy and they begin therapy on the second or third day
following the onset of menses. Effective contraception should be continued throughout
SPORANOX therapy and for 2 months following the end of treatment.
Nursing Mothers: Itraconazole is excreted in human milk; therefore, the expected benefits
of SPORANOX therapy for the mother should be weighed against the potential risk from
exposure of itraconazole to the infant. The U.S. Public Health Service Centers for Disease
Control and Prevention advises HIV-infected women not to breast-feed to avoid potential
transmission of HIV to uninfected infants.
Pediatric Use: The efficacy and safety of SPORANOX have not been established in
pediatric patients. No pharmacokinetic data on SPORANOX Capsules are available in
children. A small number of patients ages 3 to 16 years have been treated with 100 mg/day
of itraconazole capsules for systemic fungal infections, and no serious unexpected adverse
effects have been reported. SPORANOX Oral Solution (5 mg/kg/day) has been
administered to pediatric patients (N=26; ages 6 months to 12 years) for 2 weeks and no
serious unexpected adverse events were reported.
The long-term effects of itraconazole on bone growth in children are unknown. In three
toxicology studies using rats, itraconazole induced bone defects at dosage levels as low as
20 mg/kg/day (2.5x MRHD). The induced defects included reduced bone plate activity,
thinning of the zona compacta of the large bones, and increased bone fragility. At a dosage
level of 80 mg/kg/day (10x MRHD) over 1 year or 160 mg/kg/day (20x MRHD) for 6 months,
itraconazole induced small tooth pulp with hypocellular appearance in some rats. No such
bone toxicity has been reported in adult patients.
HIV-Infected Patients: Because hypochlorhydria has been reported in HIV-infected
individuals, the absorption of itraconazole in these patients may be decreased.
ADVERSE REACTIONS
SPORANOX has been associated with rare cases of serious hepatotoxicity, including liver
failure and death. Some of these cases had neither pre-existing liver disease nor a serious
underlying medical condition. If clinical signs or symptoms develop that are consistent with
liver disease, the risks and benefits of continued SPORANOX use should be reassessed.
(See WARNINGS: Hepatic Effects and PRECAUTIONS: Information for Patients.)
Adverse Events in the Treatment of Systemic Fungal Infections
Adverse event data were derived from 602 patients treated for systemic fungal disease in
U.S. clinical trials who were immunocompromised or receiving multiple concomitant
medications. Treatment was discontinued in 10.5% of patients due to adverse events. The
median duration before discontinuation of therapy was 81 days (range: 2 to 776 days). The
table lists adverse events reported by at least 1% of patients.
Treatment of Systemic Fungal Infections:
Adverse Events Occurring with an Incidence of Greater than or Equal to 1%
*Rash tends to occur more frequently in immunocompromised patients receiving
immunosuppressive medications.
Adverse events infrequently reported in all studies included constipation, gastritis,
depression, insomnia, tinnitus, menstrual disorder, adrenal insufficiency, gynecomastia, and
male breast pain.
Adverse Events Reported in Toenail Onychomycosis Clinical Trials
Patients in these trials were on a continuous dosing regimen of 200 mg once daily for 12
consecutive weeks.
The following adverse events led to temporary or permanent discontinuation of therapy.
Clinical Trials of Onychomycosis of the Toenail:
Adverse Events Leading to Temporary or Permanent Discontinuation of
Therapy
The following adverse events occurred with an incidence of greater than or equal to 1%
(N=112): headache: 10%; rhinitis: 9%; upper respiratory tract infection: 8%; sinusitis, injury:
7%; diarrhea, dyspepsia, flatulence, abdominal pain, dizziness, rash: 4%; cystitis, urinary
tract infection, liver function abnormality, myalgia, nausea: 3%; appetite increased,
constipation, gastritis, gastroenteritis, pharyngitis, asthenia, fever, pain, tremor, herpes
zoster, abnormal dreaming: 2%.
Adverse Events Reported in Fingernail Onychomycosis Clinical Trials
Patients in these trials were on a pulse regimen consisting of two 1-week treatment periods
of 200 mg twice daily, separated by a 3-week period without drug.
The following adverse events led to temporary or permanent discontinuation of therapy.
Clinical Trials of Onychomycosis of the Fingernail:
Adverse Events Leading to Temporary or Permanent Discontinuation of
Therapy
The following adverse events occurred with an incidence of greater than or equal to 1%
(N=37): headache: 8%; pruritus, nausea, rhinitis: 5%; rash, bursitis, anxiety, depression,
constipation, abdominal pain, dyspepsia, ulcerative stomatitis, gingivitis,
hypertriglyceridemia, sinusitis, fatigue, malaise, pain, injury: 3%.
Post-marketing Experience
In worldwide post-marketing experience with SPORANOX Capsules in treatment of
onychomycosis and/or systemic fungal infections, peripheral edema, allergic reactions,
including rash, pruritus, urticaria, angioedema, and, in rare instances, anaphylaxis and
Stevens-Johnson syndrome, have been reported. Post-marketing experiences have also
included reports of elevated liver enzymes and rarely liver failure. Rare cases of congestive
heart failure and pulmonary edema have been reported. Rare cases of alopecia,
hypertriglyceridemia, menstrual disorders, and neutropenia, and isolated cases of
neuropathy have also been reported, although the causal association with SPORANOX is
uncertain. (See CLINICAL PHARMACOLOGY: Special Populations,
CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS: Drug Interactions for more
information).
OVERDOSAGE
Itraconazole is not removed by dialysis. In the event of accidental overdosage, supportive
measures, including gastric lavage with sodium bicarbonate, should be employed.
Limited data exist on the outcomes of patients ingesting high doses of itraconazole. In
patients taking either 1000 mg of SPORANOX (itraconazole) Oral Solution or up to 3000
mg of SPORANOX (itraconazole) Capsules, the adverse event profile was similar to that
observed at recommended doses.
DOSAGE AND ADMINISTRATION
SPORANOX Capsules is a different preparation than SPORANOX Oral Solution and
should not be used interchangeably.
Treatment of Blastomycosis and Histoplasmosis: The recommended dose is 200 mg
once daily (2 capsules). If there is no obvious improvement, or there is evidence of
progressive fungal disease, the dose should be increased in 100-mg increments to a
maximum of 400 mg daily. Doses above 200 mg/day should be given in two divided
doses.
Treatment of Aspergillosis: A daily dose of 200 to 400 mg is recommended.
Treatment in Life-Threatening Situations: In life-threatening situations, a loading dose
should be used whether given as oral capsules or intravenously.
IV Injection: the recommended intravenous dose is 200 mg b.i.d. for four consecutive
doses, followed by 200 mg once daily thereafter. Each intravenous dose should be
infused over 1 hour. The safety and efficacy of SPORANOX Injection administered for
greater than 14 days is not known. See complete prescribing information for
SPORANOX (itraconazole) Injection.
Capsules: although clinical studies did not provide for a loading dose, it is
recommended, based on pharmacokinetic data, that a loading dose of 200 mg (2
capsules) three times daily (600 mg/day) be given for the first 3 days of treatment.
Treatment should be continued for a minimum of three months and until clinical parameters
and laboratory tests indicate that the active fungal infection has subsided. An inadequate
period of treatment may lead to recurrence of active infection.
SPORANOX Capsules and SPORANOX Oral Solution should not be used
interchangeably. Only the oral solution has been demonstrated effective for oral and/or
esophageal candidiasis.
Treatment of Onychomycosis: Toenails with or without fingernail involvement: The
recommended dose is 200 mg (2 capsules) once daily for 12 consecutive weeks.
Treatment of Onychomycosis: Fingernails only: The recommended dosing regimen is 2
treatment pulses, each consisting of 200 mg (2 capsules) b.i.d. (400 mg/day) for 1 week.
The pulses are separated by a 3-week period without SPORANOX.
HOW SUPPLIED
SPORANOX (itraconazole) Capsules are available containing 100 mg of itraconazole,
with a blue opaque cap and pink transparent body, imprinted with �JANSSEN� and
�SPORANOX 100.� The capsules are supplied in unit-dose blister packs of 3 x 10
capsules (NDC 50458-290-01), bottles of 30 capsules (NDC 50458-290-04) and in the
PulsePak� containing 7 blister packs x 4 capsules each (NDC 50458-290-28).
Store at controlled room temperature 15�-25�C (59�-77�F). Protect from light and moisture.
- To bookmark this page (add it to your favorites), please click the image to the left.
- If you wish to link to this page, you can do so by referring to the URL address below this line.
https://theodora.com/drugs/sporanox_itraconazole_capsules_janssen.html